---
title: "TransCode Therapeutics, Inc. (RNAZ.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RNAZ.US.md"
symbol: "RNAZ.US"
name: "TransCode Therapeutics, Inc."
industry: "Biotechnology"
datetime: "2026-06-13T17:57:19.785Z"
locales:
  - [en](https://longbridge.com/en/quote/RNAZ.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RNAZ.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RNAZ.US.md)
---

# TransCode Therapeutics, Inc. (RNAZ.US)

## Company Overview

TransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company’s therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.transcodetherapeutics.com](https://www.transcodetherapeutics.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.12 | 79 | - | - | - |
| PB | 4.05 | 301 | 5.78 | 2.02 | 0.89 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-04-16T04:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Overweight | 1 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 5.33 |
| Highest Target | undefined |
| Lowest Target | undefined |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RNAZ.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RNAZ.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RNAZ.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RNAZ.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**